Acrobiosystems for English
icon_bulk_orderAchat groupé/Commande rapide
user
  1. Tableau de bord
  2. Mon profil
  3. Mon adresse
  4. Mes commandes
  5. Adhésion à Acro
Connexion Inscription
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
Il n'y a pas de produit dans le panier !
Mon panier|Check Out
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > PCSK9

PCSK9

Brief Information

Name:Proprotein convertase subtilisin kexin type 9
Target Synonym:EC 3.4.21,Neural apoptosis-regulated convertase 1,Proprotein convertase 9,NARC1,PSEC0052,PCSK9,NARC-1,EC:3.4.21.-,Proprotein Convertase Subtilisin/Kexin Type 9,Subtilisin/Kexin-Like Protease PC9,PC9,Convertase Subtilisin/Kexin Type 9 Preproprotein,Hypercholesterolemia, Autosomal Dominant 3,EC 3.4.21.-,HCHOLA3,LDLCQ1,FH3,EC 3.4.21.111,Neural Apoptosis Regulated Convertase 1,FHCL3
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:27
Lastest Research Phase:Approved

Product ListCompare or Buy

Product> Filter Results
Par statut du produit :
Par catégorie de produit :
Par espèce :
Par étiquette :
Par conjugaison :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
CEA-C202 Human ClinMax™ Human PCSK9 ELISA Kit
PC9-H52H7 Human Human PCSK9 Protein, His Tag
PC9-H52H7-structure
PC9-H52H7-sds
EP-103 Human PCSK9 [Biotinylated] : LDL R Inhibitor Screening ELISA Assay Pair
PC9-H5256 Human Human PCSK9 Protein, Fc Tag
PC9-H5256-structure
PC9-H5256-sds
PC9-H52E4 Hamster Hamster PCSK9 Protein, His Tag
PC9-H52E4-structure
PC9-H52E4-sds
PC9-C5223 Cynomolgus Cynomolgus PCSK9 Protein, His Tag
PC9-C5223-structure
PC9-C5223-sds
PC9-M82E1 Mouse Biotinylated Mouse PCSK9 Protein, Avitag™,His Tag
PC9-M82E1-structure
PC9-M82E1-sds
PCY-H5225 Human Human PCSK9 (D374Y) Protein, His Tag (MALS verified)
PCY-H5225-structure
PCY-H5225-sds
PC9-C52H2 Rhesus macaque Rhesus macaque PCSK9 Protein, His Tag
PC9-C52H2-structure
PC9-C52H2-sds
PC9-R52H4 Rat Rat PCSK9 Protein, His Tag
PC9-R52H4-structure
PC9-R52H4-sds
PCY-H82E7 Human Biotinylated Human PCSK9 (D374Y) Protein, Avitag™,His Tag
PCY-H82E7-structure
PCY-H82E7-sds
PC9-H82E7 Human Biotinylated Human PCSK9 Protein, Avitag™,His Tag (MALS verified)
PC9-H82E7-structure
PC9-H82E7-sds
PC9-M5228 Mouse Mouse PCSK9 Protein, His Tag
PC9-M5228-structure
PC9-M5228-sds
PC9-H5223 Human Human PCSK9 Protein, His Tag (MALS Verified)
PC9-H5223-structure
PC9-H5223-sds
ACRO Quality

Part of Bioactivity data

PCY-H5225-Cell-based assay
PCSK9 FACS

FACS analysis shows that Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) inhibits LDL uptake in HepG2 cells. The EC50 for this effect is 0.0689-0.3049 μg/mL.

Protocol
PCY-H5225-Cell-based assay
PCSK9 FACS

FACS analysis shows that the effect of Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) inhibiting LDL uptake in HepG2 cells was neutralized by Anti-Human PCSK9 antibody. The concentration of PCSK9 used is 5 μg/mL. The EC50 for Anti-Human PCSK9 antibody is 6.816-12.67 μg/mL.

Protocol
PC9-H5256-BLI
PCSK9 BLI

Loaded Human PCSK9, Fc Tag (Cat. No. PC9-H5256) on Protein A Biosensor, can bind Human LDL R, His Tag (Cat. No. LDR-H5224) with an affinity constant of 12.7 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol
PC9-H52E4-BLI
PCSK9 BLI

Loaded Human LDL R, Fc Tag on Protein A Biosensor, can bind Hamster PCSK9, His Tag (Cat. No. PC9-H52E4) with an affinity constant of 4.09 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

Customer Reviews

Synonym Name

PCSK9,FH3,HCHOLA3,LDLCQ1,NARC1,PC9

Background

Proprotein convertase subtilisin/kexin type 9 (PCSK9), is an enzyme which in humans is encoded by the PCSK9 gene.This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. This protein plays a major regulatory role in cholesterol homeostasis. PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. PCSK9 may also have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a rare form of autosomal dominant familial hypercholesterolemia (HCHOLA3).

Clinical and Translational Updates

Related Molecule

LDL R

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Inclisiran sodium ALN-60212; PCSK9si; ALN-PCSsc; KJX839; KJX-839 Approved Alnylam Pharmaceuticals Inc Leqvio, 乐可为 EU Dyslipidemias; Hypercholesterolemia Novartis Europharm Ltd 2020-12-09 Acute Coronary Syndrome; Diabetes Mellitus; Hyperlipidemias; Hyperlipoproteinemia Type II; Cardiovascular Diseases; Dyslipidemias; Coronary Disease; Heterozygous familial hypercholesterolemia; Hypolipoproteinemias; Stroke; Homozygous familial hypercholesterolemia; Kidney Diseases; Coronary Artery Disease; Hypercholesterolemia; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Myocardial Infarction; Atherosclerosis; Plaque, Atherosclerotic Details
Evolocumab AMG-145 Approved Amgen Inc, Astellas Pharma Inc 瑞百安, Repatha EU Dyslipidemias; Hypercholesterolemia Amgen Europe Bv 2015-07-17 Acute Coronary Syndrome; Aortic Aneurysm, Abdominal; Diabetes Mellitus; Hyperlipoproteinemia Type II; Hyperlipidemias; Glioma; Rejection in heart transplantation; Cardiovascular Diseases; Coronary Disease; Heterozygous familial hypercholesterolemia; Dyslipidemias; Stroke; HIV Infections; Sepsis; Glioblastoma; Coronary Artery Disease; Hypercholesterolemia; Heart Failure; Atherosclerosis; Myocardial Infarction; Diabetes Mellitus, Type 2; ST Elevation Myocardial Infarction; Homozygous familial hypercholesterolemia Details
Tafolecimab IBI-306 Approved Innovent Biologics(Suzhou) Co Ltd 信必乐 Mainland China Dyslipidemias; Hypercholesterolemia Innovent Biologics(Suzhou) Co Ltd 2023-08-15 Homozygous familial hypercholesterolemia; Drug-Related Side Effects and Adverse Reactions; Hypercholesterolemia; Dyslipidemias; Heterozygous familial hypercholesterolemia Details
Alirocumab 316P; REGN-727; SAR-236553 Approved Sanofi 波立达, Praluent United States Hypercholesterolemia Regeneron Pharmaceuticals Inc 2015-07-24 Stroke; Hyperlipidemias; Drinking Behavior; Cardiovascular Diseases; Coronary Disease; Vascular Diseases; Heterozygous familial hypercholesterolemia; Dyslipidemias; Acute Coronary Syndrome; Hemorrhage; Intracranial Arteriosclerosis; Angina Pectoris; Shock, Septic; Hypercholesterolemia; Sepsis; ST Elevation Myocardial Infarction; Diabetes Mellitus, Type 2; Atherosclerosis; Myocardial Infarction; Liver Diseases, Alcoholic; HIV Infections; Plaque, Atherosclerotic; Homozygous familial hypercholesterolemia Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Recombinant human anti-PCSK9 monoclonal antibody (Salubris) SAL003 Phase 3 Clinical Shenzhen Salubris Pharmaceuticals Co Ltd Hypercholesterolemia; Dyslipidemias; Hyperlipidemias; Hyperlipidemia, Familial Combined Details
Lerodalcibep LIB-003 Phase 3 Clinical Lib Therapeutics Llc Atherosclerosis; Hypercholesterolemia; Stroke; Heterozygous familial hypercholesterolemia; Cardiovascular Diseases; Arteriosclerosis; Hyperlipoproteinemia Type II Details
MK-0616 MK-0616 Phase 3 Clinical Merck Sharp & Dohme Corp Atherosclerosis; Hypercholesterolemia; Kidney Diseases; Cardiovascular Diseases; Arteriosclerosis; Hyperlipoproteinemia Type II Details
AZD-8233 AZD-8233; IONIS-AZ4-2.5-LRx; ION-449 Phase 2 Clinical Ionis Pharmaceuticals Inc Hypercholesterolemia; Dyslipidemias; Hyperlipidemias; Kidney Failure, Chronic Details
CiVi-007 CiVi-007; LNA-PCSK -9; LNA-PCSK9-GalNac Phase 2 Clinical F. Hoffmann-La Roche Ltd Hypercholesterolemia Details
CVI-LM-001 CVI-LM-001; CVI-LM001; C-8304 Phase 2 Clinical Xiwei'Ai Medicine Technology (Shanghai) Co Ltd Hypercholesterolemia; Hyperlipidemias Details
ATX-304 O-304; ATX-304; O-304X Phase 2 Clinical Betagenon Ab Mitochondrial Diseases; Diabetes Mellitus, Type 2; Peripheral Arterial Disease Details
MIL-86 MIL-86 Phase 2 Clinical Beijing Mabworks Biotech Co Ltd Hypercholesterolemia; Heterozygous familial hypercholesterolemia; Cardiovascular Diseases; Hyperlipidemias; Hyperlipoproteinemia Type II Details
NNC0385-0434 NNC0385-0434 Phase 2 Clinical Novo Nordisk A/S Plaque, Atherosclerotic; Diabetes Mellitus, Type 2; Hypercholesterolemia; Cardiovascular Diseases; Renal Insufficiency, Chronic; Arteriosclerosis Details
AZD-0780 AZD-0780; AZD0780 Phase 2 Clinical Dogma Therapeutics Dyslipidemias; Cardiovascular Diseases Details
Recombinant human anti-PCSK9 monoclonal antibody (Tasly Pharm) B1655; B-1655 Phase 1 Clinical Tianjin Tasly Pharmaceutical Co Ltd Hypercholesterolemia Details
DC-371739 JYP-0739; DC-371739 Phase 1 Clinical Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Hypercholesterolemia; Dyslipidemias; Hyperlipidemias Details
Anti-PCSK9 monoclonal antibody (Biocad) Phase 1 Clinical Biocad Cardiovascular Diseases Details
ATH-04 ATH-04; Affitope AT04A Phase 1 Clinical Affiris Ag Atherosclerosis Details
VERVE-101 VERVE-101 Phase 1 Clinical Broad Institute, Harvard University Plaque, Atherosclerotic; Hypercholesterolemia; Heterozygous familial hypercholesterolemia Details
SAL-092 SAL092; SAL-092 Phase 1 Clinical Shenzhen Salubris Pharmaceuticals Co Ltd Hypercholesterolemia; Dyslipidemias Details
SYH-2053 SYH2053; SYH-2053 Phase 1 Clinical CSPC Pharmaceutical Group Ltd Hypercholesterolemia; Dyslipidemias; Hyperlipidemia, Familial Combined; Hyperlipidemias Details
VERVE-102 VERVE-102 Phase 1 Clinical Verve Therapeutics Inc Atherosclerosis; Coronary Disease; Heterozygous familial hypercholesterolemia Details
SGB-3403 SGB-3403 Phase 1 Clinical Suzhou Sanegene Biopharmaceuticals Ltd Atherosclerosis; Hypercholesterolemia; Heterozygous familial hypercholesterolemia; Cardiovascular Diseases; Hyperlipidemias Details
RN-0191 RN0191 Phase 1 Clinical Rona Therapeutics Inc Atherosclerosis; Hypercholesterolemia; Dyslipidemias Details
RBD-7022 RBD-7022; RBD7022 Phase 1 Clinical Suzhou Ribo Life Science Co Ltd Hypercholesterolemia; Hyperlipidemias; Hyperlipidemia, Familial Combined Details
JX-7002 JX7002; JX-7002 Phase 1 Clinical Zhejiang Jingxin Pharmaceutical Co Ltd Hypercholesterolemia; Hyperlipidemias Details
NN-6434 NN-6434 Phase 1 Clinical Novo Nordisk A/S Details
PCSK9 modulator (Genekey Biotech) Phase 1 Clinical Shenzhen Salubris Pharmaceuticals Co Ltd Metabolic Diseases; Inflammation Details

This web search service is supported by Google Inc.

totop
Call us
Call us

Germany+49 800 0826645

United Kingdom+44 808 281 3436

Netherlands+31 800 0224992

Switzerland+41 800 040 012

France+33 800 90 78 85

Sweden+46 20 12 76 94

Denmark+45 80 83 07 62

Belgium+32 800 27 125

Email
E-Mail
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland
linkedin twitter facebook youtube

Laisser un message

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap